January 22, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Adial Pharmaceuticals, Inc. | ||
| Registration Statement on Form S-1 | |||
|
Filed January 12, 2024 File No: 333-276496 |
Dear Sir or Madam:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3, as amended (File No. 333-276496), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Wednesday, January 24, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
| Very truly yours, | |||
| ADIAL PHARMACEUITCALS, INC. | |||
| By: | /s/ Cary Claiborne | ||
| Name: | Cary Claiborne | ||
| Title: | Chief Executive Officer | ||
| cc: | Leslie Marlow, Blank Rome LLP | |
| Hank Gracin, Blank Rome LLP |